Pricing Log in Create free account

Braveheart Bio, Inc. (BRVE) vs Ultragenyx Pharmaceutical Inc. (RARE)

Braveheart Bio, Inc. and Ultragenyx Pharmaceutical Inc. are both Biotechnology companies. Braveheart Bio, Inc. and Ultragenyx Pharmaceutical Inc. are of similar size ($1.6B and $1.5B). Braveheart Bio, Inc. has the higher net margin (0.00% vs −71.8%) and the higher return on invested capital (0.00% vs 0.00%). Across the 9 metrics below, Braveheart Bio, Inc. leads on 8 and Ultragenyx Pharmaceutical Inc. on 1.

Valuation

Metric BRVE RARE Biotechnology median
P/E — n/m 10.60
P/S n/m 2.17 9.40
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 1.80 9.02
Earnings yield — (33.48%) (32.88%)
Free cash flow yield (16.31%) (28.26%) (23.13%)

Profitability

Metric BRVE RARE Biotechnology median
Gross margin — 82.88% 68.51%
Operating margin 0.00% (63.97%) 0.00%
Net margin 0.00% (71.78%) 0.00%
Free cash flow margin 0.00% (61.23%) 0.00%
Return on equity 0.00% 285.68% (51.96%)
Return on assets 0.00% (44.08%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BRVE RARE Biotechnology median
Revenue growth (TTM) — 15.75% 6.76%
EPS growth (last fiscal year) — 7.31% 29.88%
Revenue growth, 5-year CAGR — 19.95% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric BRVE RARE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 13.63 1.40 4.97
Net debt to EBITDA 1.34 1.35 1.01

Dividend

Metric BRVE RARE Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BRVE RARE Biotechnology median
Market cap 1.57b 1.54b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack